Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts
Niels Peek,Gerhard Hindricks,Artur Akbarov,Jan G P Tijssen,David A Jenkins,Zoher Kapacee,Le Mai Parkes,Rob J van der Geest,Enrico Longato,Daniel Sprague,Youssef Taleb,Marcus Ong,Christopher A Miller,Alireza Sepehri Shamloo,Christine Albert,Petra Barthel,Serge Boveda,Frieder Braunschweig,Jens Brock Johansen,Nancy Cook,Christian de Chillou,Petra Elders,Jonas Faxén,Tim Friede,Laura Fusini,Chris P Gale,Jiri Jarkovsky,Xavier Jouven,Juhani Junttila,Josef Kautzner,Antti Kiviniemi,Valentina Kutyifa,Christophe Leclercq,Daniel C Lee,Jill Leigh,Radosław Lenarczyk,Francisco Leyva,Michael Maeng,Andrea Manca,Eloi Marijon,Ursula Marschall,Jose Luis Merino,Lluis Mont,Jens Cosedis Nielsen,Thomas Olsen,Julie Pester,Gianluca Pontone,Ivo Roca,Georg Schmidt,Peter J Schwartz,Christian Sticherling,Mahmoud Suleiman,Milos Taborsky,Hanno L Tan,Jacob Tfelt-Hansen,Holger Thiele,Gordon F Tomaselli,Tom Verstraelen,Manickavasagar Vinayagamoorthy,Kevin Kris Warnakula Olesen,Arthur Wilde,Rik Willems,Katherine C Wu,Markus Zabel,Glen P Martin,Nikolaos Dagres
DOI: https://doi.org/10.1093/eurheartj/ehae326
2024-10-08
Abstract:Background and aims: Risk stratification of sudden cardiac death after myocardial infarction and prevention by defibrillator rely on left ventricular ejection fraction (LVEF). Improved risk stratification across the whole LVEF range is required for decision-making on defibrillator implantation. Methods: The analysis pooled 20 data sets with 140 204 post-myocardial infarction patients containing information on demographics, medical history, clinical characteristics, biomarkers, electrocardiography, echocardiography, and cardiac magnetic resonance imaging. Separate analyses were performed in patients (i) carrying a primary prevention cardioverter-defibrillator with LVEF ≤ 35% [implantable cardioverter-defibrillator (ICD) patients], (ii) without cardioverter-defibrillator with LVEF ≤ 35% (non-ICD patients ≤ 35%), and (iii) without cardioverter-defibrillator with LVEF > 35% (non-ICD patients >35%). Primary outcome was sudden cardiac death or, in defibrillator carriers, appropriate defibrillator therapy. Using a competing risk framework and systematic internal-external cross-validation, a model using LVEF only, a multivariable flexible parametric survival model, and a multivariable random forest survival model were developed and externally validated. Predictive performance was assessed by random effect meta-analysis. Results: There were 1326 primary outcomes in 7543 ICD patients, 1193 in 25 058 non-ICD patients ≤35%, and 1567 in 107 603 non-ICD patients >35% during mean follow-up of 30.0, 46.5, and 57.6 months, respectively. In these three subgroups, LVEF poorly predicted sudden cardiac death (c-statistics between 0.50 and 0.56). Considering additional parameters did not improve calibration and discrimination, and model generalizability was poor. Conclusions: More accurate risk stratification for sudden cardiac death and identification of low-risk individuals with severely reduced LVEF or of high-risk individuals with preserved LVEF was not feasible, neither using LVEF nor using other predictors.